针对型肝炎病毒 (HCV) 进入的抑制剂
Paulo Fernando da Silva Santos-Júnior1, João Xavier de Araújo-Júnior1,2, Edeildo Ferreira da Silva-Júnior1
1Institute of Chemistry and Biotechnology, Federal University of Alagoas, Campus A.C. Simões, LourivalMeloMota Avenue, Maceió, 57072-970, Brazil.
Mini reviews in medicinal chemistry
|July 10, 2023
概括
型肝炎病毒 (HCV) 进入抑制剂对于开发新疗法至关重要,因为目前的直接作用抗病毒药物 (DAA) 并非对所有人有效. 这次审查强调了有希望的化合物,这些化合物针对HCV的进入,包括ITX 5061和环.
科学领域:
- 病毒学 病毒学
- 肝病学 肝病学是一种肝病学.
- 药物发现 药物发现 药物发现
背景情况:
- 型肝炎病毒 (HCV) 感染影响全球7000万,导致严重的肝病和肝细胞癌.
- 尽管有直接作用的抗病毒药物 (DAA),但5-10%的患者无法清除病毒,并且没有疫苗存在.
- 病毒进入是开发针对HCV的新型抗病毒策略的关键目标.
结论:
- 准HCV的入侵是开发新抗病毒疗法的可行策略.
- ITX 5061和环素是有效的入抑制剂的显著例子.
- 对这些抑制剂及其SAR的进一步研究可以促进HCV治疗.
相关概念视频
Enzyme Inhibition
78.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.8K
Eukaryotic Transcription Inhibitors
9.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.9K
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214


